Blood glucose levels in patients not hospitalized vaccinated against SARS-CoV-2 viral infection as risk factor for severe Covid-19

Andressa de Farias Fehlberg 1, Lorena Gonçalves da Silva Salles 1, 2, Yasmin Lima de Oliveira 1, 3, Andreza Mendes da Silva 1, 4, Cintia de Oliveira Correa 1, 4, Joelma Lessa da Silva 1 and Rachel Siqueira de Queiroz Simões 1, 5, 6, *

1 Department of Sciences Medicine, All Lab World Medical Clinic, Presidente Vargas, 529 - Centro, Rio de Janeiro, Brazil.
2 Department of Pharmacy, Celso Lisboa University Centre, Rio de Janeiro, Brazil.
3 Department of Biomedicine, Celso Lisboa University Centre, Rio de Janeiro, Brazil.
4 Department of Nursing, Celso Lisboa University Centre, Rio de Janeiro, Brazil.
5 Department of Health and Agricultural Sciences, Santa Úrsula University, Fernando Ferrari, 75 – Botafogo, Rio de Janeiro, Brazil.
6 Vector Medical Malacology lato sensu postgraduate, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brazil 4.365 – Manguinhos, Rio de Janeiro, Brazil.
 
Research Article
International Journal of Frontiers in Chemistry and Pharmacy Research, 2024, 05(01), 001–006.
Article DOI: 10.53294/ijfcpr.2024.5.1.0025
Publication history: 
Received on 16 July 2024; revised on 04 September 2024; accepted on 06 September 2024
 
Abstract: 
Hyperglycemia or diabetic people has been suggested as a risk factor for developing severe illness from coronavirus disease 2019 (COVID-19). The aim of our study was to detect the presence of glucose levels in blood samples of the patients without known pre-existing diabetes collected in the post-pandemic period. Patients with severe COVID-19 pneumonia requiring hospitalization between January 2023 and December 2023 were not enrolled in this retrospective observational study. This is a retrospective epidemiology study involving patients categorized into three groups according to admission Blood Glucose (BG) levels: < 70 mg/dL; 77 – 90 mg/dL; > 99 mg/dL collected in 2023y according to standard glycaemia targets. Throughout 2023y, a total of 13,246 blood samples were collected from 11,425 non-diabetic patients vaccinated against Covid, which 10,478 male and 947 female. Furthermore, we detected that nondiabetic patients with good glycemic control (86.77%). Moreover, we detected highest percentage of samples collected from men (91,71%) and lowest percentage from women (8,28%). These data upon the references resulted as hyperglycaemia were compared to COVID-19 vaccinated patients with normoglycemia blood glucose measures. So, our study dataset was a backward-looking study which the glucose parameter listed in the electronic medical records could be analyzed as focuses the predictor factor on vaccinated patients against SARS-CoV-2. We concluded that new insulin therapy could be applied in future studies including diabetic patients vaccinated against COVID-19. It is also added that comorbidities were not considered in the analysis of controlled glucose levels and/or considered within the normal reference standard.

 

Keywords: 
SARS-Cov-2; COVID-19; Diabetes; Blood Glucose; Hyperglycaemia.
 
Full text article in PDF: 
 
Copyright information: 
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0